Human immunodeficiency virus infection and viral hepatitis;Infección por virus de la inmunodeficiencia humana y hepatitis víricas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 9, 2011, Pages 691-701

  Soriano, Vicente ^a   Martin Carbonero, Luz ^a   Vispo, Eugenia ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Boceprevir; Delta hepatitis; Hepatitis B; Hepatitis C; HIV; Telaprevir; Tenofovir

Indexed keywords

BOCEPREVIR; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CONSULTATION; DELTA AGENT HEPATITIS; EPIDEMIC; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MIXED INFECTION; PROGNOSIS; VACCINATION; VIRUS HEPATITIS;

ALGORITHMS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COMORBIDITY; DISEASE PROGRESSION; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; RECURRENCE;

EID: 80054944399     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.07.003     Document Type: Article

References (95)

1. I. Bica, B. McGovern, R. Dhar, D. Stone, K. McGowan, and R. Scheib Increasing mortality due to end-stage liver disease in patients with HIV infection Clin Infect Dis 32 2001 492 497 (Pubitemid 32173638)
2. M. Puoti, M. Airoldi, R. Bruno, B. Zanini, A. Spinetti, and C. Pezzoli Hepatitis B virus co-infection in HIV-infected subjects AIDS Rev 4 2002 27 35 (Pubitemid 34464232)
3. M. Núñez, M. Puoti, N. Camino, and V. Soriano Treatment of chronic hepatitis B in the HIV-infected patient: present and future Clin Infect Dis 37 2003 1678 1685 (Pubitemid 37549956)
4. C. Thio, E. Seaberg, R. Skolasky, J. Phair, B. Visscher, and A. Muñoz HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) Lancet 360 2002 1921 1926 (Pubitemid 35472132)
5. G. Dore, V. Soriano, J. Rockstroh, B. Kupfer, E. Tedaldi, and L. Peters Frequent hepatitis B virus rebound among HIV-HBV coinfected patients following antiretroviral therapy interruption AIDS 24 2010 857 865
6. M. Núñez, and V. Soriano Hepatotoxicity of antiretrovirals: incidence, mechanisms and management Drug Saf 28 2005 53 66
7. V. Di Martino, T. Thevenot, J. Colin, N. Boyer, H. Martinot, and F. Degos Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B Gastroenterology 123 2002 1812 1822 (Pubitemid 35408305)
8. M. Núñez, P. Ríos, M. Pérez-Olmeda, and V. Soriano Lack of occult hepatitis B virus infection in HIV-infected patients AIDS 16 2002 2099 2101 (Pubitemid 35205282)
9. J. Hoff, F. Bani-Sadr, M. Gassin, and F. Raffi Evaluation of chronic hepatitis B virus (HBV) infection in co-infected patients receiving lamivudine as component of anti-HIV regimen Clin Infect Dis 32 2001 963 969 (Pubitemid 32524830)
10. Y. Benhamou, M. Bochet, V. Thibault, V. Di Martino, E. Caumes, and F. Bricaire Long term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients Hepatology 30 1999 1303 1306
11. D. Pillay, P. Cane, D. Ratcliffe, M. Atkins, and D. Cooper Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR coordinating committee AIDS 14 2000 1111 1116 (Pubitemid 30420653)
12. G. Dore, D. Cooper, A. Pozniak, E. De Jesus, L. Zhong, and M.D. Miller Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy naive and experienced patients coinfected with HIV-1 and hepatitis B virus J Infect Dis 189 2004 1185 1192 (Pubitemid 38457242)
13. F. Van Bömmel, T. Wünsche, D. Schürmann, and T. Berg Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication Hepatology 36 2002 507 508 (Pubitemid 34810374)
14. M. Núñez, M. Pérez-Olmeda, B. Díaz, P. Ríos, J. González-Lahoz, and V. Soriano Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine AIDS 16 2002 2352 2354 (Pubitemid 35449029)
15. M. Ristig, J. Crippin, J. Aberg, W.G. Powderly, K. Lisker-Melman, and L. Kessels Tenofovir disoproxil fumarate therapy for chronic hepatitis B in HIV/hepatitis B virus-coinfected individuals for whom interferon and lamivudine therapy have failed J Infect Dis 186 2002 1844 1847 (Pubitemid 35463519)
16. M. Nelson, S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, and G. Matthews An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals AIDS 17 2003 F7 F10
17. Y. Benhamou, R. Tubiana, and V. Thibault Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus N Engl J Med 348 2003 177 178 (Pubitemid 36056731)
18. J. Sheldon, N. Camino, B. Rodes, A. Bartholomeusz, M. Kuiper, and F. Tacke Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir Antivir Ther 10 2005 727 734 (Pubitemid 41376852)
19. J. Sheldon, A. Corral, B. Rodes, S. Mauss, J. Rockstroh, and F. Berger Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir AIDS 19 2005 2036 2038 (Pubitemid 41669031)
20. Y. Benhamou, M. Bochet, V. Thibault, V. Calvez, M.H. Frevet, and P. Vig Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study Lancet 358 2001 718 723 (Pubitemid 32823401)
21. R. Gish, N. Leung, T. Wright, H. Trinh, W. Lang, and H.A. Kessler Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection Antimicrob Agents Chemother 46 2002 1734 1740 (Pubitemid 34535190)
22. H. Kwon, and A. Lok Hepatitis B therapy Nat Rev Gastroenterol Hepatol 8 2011 275 284
23. G. Brook, V. Soriano, and C. Bergin European guideline for the management of hepatitis B and C virus infections, 2010 Int J STD AIDS 21 2010 669 678
24. V. Soriano, M. Puoti, M. Bonacini, Y. Benhamou, M. Sulkowski, and F. Zoulim Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel AIDS 22 2008 1399 1410.
25. L. Martín-Carbonero, V. Soriano, E. Valencia, J. García-Samaniego, M. López, and J. González-Lahoz Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients AIDS Res Hum Retroviruses 17 2001 1467 1472
26. R. Weber, C. Sabin, N. Friis-Moller, P. Reiss, W.M. El-Sadr, and O. Kirk Liver-related deaths in persons with the HIV: the D:A:D study Arch Intern Med 166 2006 1632 1641
27. M. Nuñez Clinical syndromes and consequences of antiretroviral-realted hepatotoxicity Hepatology 52 2010 1143 1155
28. V. Soriano, M. Puoti, P. Garcia-Gasco, J. Rockstroh, Y. Benhamou, and P. Barreiro Antiretroviral drugs and liver injury AIDS 22 2008 1 13 (Pubitemid 350301936)
29. J. Rockstroh, A. Mocroft, V. Soriano, C. Tural, M. Losso, and A. Borban Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy J Infect Dis 192 2005 992 1002 (Pubitemid 41266795)
30. A. Rauch, M. Rickenbach, R. Weber, B. Hirschel, Tarr Pe, and H. Buchar Association of unsafe sex and increased incidence of hepatitis C infection in HIV-infected men who have sex with men Clin Infect Dis 41 2005 395 402 (Pubitemid 41022120)
31. E. Low, M. Vogel, J. Rockstroh, and M. Nelson Acute hepatitis C in HIV-positive individuals AIDS Rev 10 2008 245 253
32. European AIDS Treatment Network (NEAT) Acute hepatitis C in HIV-infected individuals: recommendatiosn from the European AIDS RTreatment Network (NEAT) consensus conference AIDS 25 2011 399 409
33. V. Soriano, M. Puoti, M. Sulkowski, A. Cargnel, Y. Benhamou, and M. Peters Care of patients coinfected with HIV and hepatitis C virus: updated recommendations from the HIV-HCV International Panel AIDS 21 2007 1073 1089 (Pubitemid 46763278)
34. V. Soriano, A. Mocroft, J. Rockstroh, B. Ledergerber, B. Knysz, and S. Chaplinskas Spontaneous viral clearance, viral load, and genotype distribution of HCV in HIV-infected patients with HCV antibodies in Europe J Infect Dis 198 2008 1337 1344
35. B. Cribier, D. Rey, C. Schmitt, J.M. Lang, A. Kirn, and F. Stoll-Keller High hepatitis C viremia and impaired antibody response in patients coinfected with HIV AIDS 9 1995 1131 1136
36. I. Maida, V. Soriano, P. Barreiro, P. Rivas, P. Labarga, and M. Núñez Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases AIDS Res Hum Retroviruses 23 2007 801 804 (Pubitemid 47047919)
37. G. Greub, B. Ledergerber, M. Battegay, P. Grob, L. Perrin, and H. Furrer Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfections Lancet 356 2000 1800 1805
38. V. Soriano, J.C. Martín, and J. González-Lahoz HIV-1 progression in hepatitis C-infected drug users Lancet 357 2001 1361 1362
39. M. Sulkowski, R. Moore, S. Mehta, R. Chaisson, and D. Thomas Hepatitis C and progression of HIV disease JAMA 288 2002 199 206 (Pubitemid 34755280)
40. A. Mocroft, A. Phillips, V. Soriano, J. Rockstroh, A. Blaxhult, and C. Katlama Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection AIDS Res Hum Retroviruses 21 2005 527 536 (Pubitemid 40944314)
41. M. Núñez, P. Ríos, L. Martín-Carbonero, M. Pérez-Olmeda, J. González-Lahoz, and V. Soriano Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy J Acquir Immun Defic Syndr 30 2002 65 68 (Pubitemid 34506688)
42. E. Vispo, A. Mena, I. Maida, F. Blanco, M. Córdoba, and P. Labarga Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C J Antimicrob Chemother 65 2010 543 547
43. D. Thomas, J. Astemborski, R. Rai, F.A. Anania, M. Schaeffer, and N. Galai The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA 284 2000 450 456 (Pubitemid 30484478)
44. M. Beld, M. Penning, V. Lukashov, H. McMorrow, M. Ross, and N. Pakker Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters Virology 244 1998 504 512 (Pubitemid 28384112)
45. M. Bonacini, S. Govindarajan, L. Blatt, P. Schmid, A. Conrad, and K. Lindsay Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV-RNA J Viral Hepat 6 1999 203 208 (Pubitemid 29260103)
46. N. Rallón, M. López, V. Soriano, J. García- Samaniego, M. Romero, and P. Labarga Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with HIV and/or hepatitis C virus Clin Exp Immunol 155 2009 35 43
47. E. Daar, H. Lynn, and S. Donfield HCV load is associated with HIV-1 disease progression in hemophiliacs J Infect Dis 183 2001 589 595
48. M. Puoti, M. Bonacini, A. Spinetti, V. Putzolu, S. Govindarajan, and S. Zaltron Liver fibrosis progression is related to CD4+ cell depletion in patients with hepatitis C and HIV coinfection J Infect Dis 183 2001 134 137 (Pubitemid 32043052)
49. C. Martinez-Sierra, A. Arizcorreta, F. Diaz, R. Roldán, L. Martín-Herrera, and Pérez-Guzmán E. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV Clin Infect Dis 36 2003 491 498 (Pubitemid 36241318)
50. L. Martin-Carbonero, Y. Benhamou, M. Puoti, J. Berenguer, J. Mallolas, and C. Quereda Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C - a European collaborative study Clin Infect Dis 38 2004 128 133 (Pubitemid 38045883)
51. M. Puoti, R. Bruno, V. Soriano, F. Donato, G.B. Gaeta, and G.P. Quinzan Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome AIDS 18 2004 2285 2293 (Pubitemid 39620221)
52. N. Qurishi, C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer, and T. Sauerbruch Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection Lancet 362 2003 1708 1713 (Pubitemid 37468321)
53. F. Blanco, P. Barreiro, P. Ryan, E. Vispo, L. Martín-Carbonero, and P. Tuma Risk factors fro advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance J Viral Hepat 18 2011 11 16
54. M. Perez-Olmeda, M. Nunez, M. Romero, J. González, A. Castro, and J.R. Arribas Pegylated interferon-a2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients AIDS 17 2003 1023 1028 (Pubitemid 36549714)
55. R. Chung, J. Andersen, P. Volberding, G. Robbins, T. Liu, and K. Sherman Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459 (Pubitemid 38988594)
56. F. Carrat, F. Bani-Sadr, S. Pol, E. Roseenthal, F. Lunel-Fabiani, and A. Benzedri Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients JAMA 292 2004 2839 2848 (Pubitemid 39628231)
57. F. Torriani, M. Rodriguez-Torres, J. Rockstroh, E. Lissen, J. González-García, and A. Lazzarin Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450 (Pubitemid 38988593)
58. M. Laguno, J. Murillas, J.L. Blanco, E. Martínez, R. Miquel, and J.M. Sánchez-Tapias Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 2004 F27 F36
59. M. Nunez, C. Miralles, M.A. Berdun, E. Losada, K. Aguirrebengoa, and A. Ocampo Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial AIDS Res Human Retroviruses 23 2007 972 982 (Pubitemid 47492337)
60. V. Soriano, I. Maida, J. Garcia-Samaniego, M. Nuñez, P. Barreiro, and J. Gonzalez-Lahoz Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies Antivir Ther 9 2004 987 992 (Pubitemid 40040272)
61. J. Medrano, P. Barreiro, S. Resino, A. Madejón, P. Labarga, and P. Tuma Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients Clin Infect Dis 49 2009 1397 1401
62. M. Fried, M. Shiffman, K. Reddy, C. Smith, G. Marinos, and F.L. Goncales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
63. NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002;123:2082-99.
64. F. Torriani, R. Ribeiro, T. Gilbert, U. Schrenk, M. Clauson, and D. Pacheco HCV and HIV dynamics during HCV treatment in HIV/HCV coinfection J Infect Dis 188 2003 1498 1507
65. M. Laguno, M. Larrousse, J. Murillas, J.L. Blanco, A. León, and A. Milinkovic Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin J Acquir Immune Defic Syndr 44 2007 174 178 (Pubitemid 46292220)
66. L. Martin-Carbonero, M. Nuñez, A. Mariño, F. Alcocer, L. Bonet, and J. García-Samaniego Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C AIDS 22 2008 15 21 (Pubitemid 350294873)
67. V. Soriano, M. Nuñez, N. Camino, P. Barreiro, J. Garcia-Samaniego, and J. Gonzalez-Lahoz Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin Antivir Ther 9 2004 505 509 (Pubitemid 39150207)
68. K. Sherman, N. Shire, S. Rouster, M.G. Peters, M. James Koziel, and R.T. Chung Viral kinetics in hepatitis C or hepatitis C/HIV-infected patients Gastroenterology 128 2005 313 327 (Pubitemid 40431085)
69. M. Nunez, N. Camino, B. Ramos, M.A. Berdún, P. Barreiro, and E. Losada Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C Antivir Ther 10 2005 657 662 (Pubitemid 41224957)
70. A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley, and T. Layden Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
71. V. Soriano, M. Pérez-Olmeda, P. Ríos, M. Núñez, J. García-Samaniego, and J. González-Lahoz Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients AIDS Res Hum Retroviruses 20 2004 351 354
72. J. Brouwer, F. Nevens, F. Bekkering, N. Bourgeois, H. Van Vlierberghe, and C.J. Weegink Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomised trial in 300 patients J Hepatol 40 2004 689 695 (Pubitemid 38367793)
73. K. Lindahl, L. Stahle, A. Bruchfeld, and R. Schvarcz High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C Hepatology 41 2005 275 279 (Pubitemid 40165370)
74. N. Dixit, J. Layden-Almer, T. Layden, and A. Perelson Modeling how ribavirin improves interferon response rates in hepatitis C virus infection Nature 432 2004 922 924 (Pubitemid 40037156)
75. A. Rendon, M. Nunez, M. Romero, P. Barreiro, L. Martín-Carbonero, and J. García-Samaniego Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients J Acquir Immune Defic Syndr 39 2005 401 405 (Pubitemid 41003783)
76. D. Dieterich Treatment of hepatitis C and anemia in HIV-infected patients J Infect Dis 185 Suppl 2 2002 128 137
77. E. Vispo, P. Labarga, J. Guardiola, P. Barreiro, P. Miralles, and R. Rubio Pre-emptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C AIDS Res Human Retroviruses 26 2010 419 424
78. M. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 Suppl 2002 237 244
79. A. Lafeuillade, G. Hittinger, and S. Chapadaud Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection Lancet 357 2001 280 281 (Pubitemid 32120863)
80. G. Moyle Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies AIDS Rev 3 2001 150 156 (Pubitemid 33121200)
81. C. De Mendoza, M. Sanchez-Conde, E. Timmermans, M. Buitelaar, M.P. De Baar, and J. Gonzalez-Lahoz Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin Antivir Ther 10 2005 557 561 (Pubitemid 41059203)
82. S. Mauss, W. Valenti, J. DePamphilis, F. Duff, L. Cupelli, and S. Passe Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrosis during interferon therapy AIDS 18 2004 F21 F25
83. F. Bani-Sadr, L. Denoeud, P. Morand, F. Lunel-Fabiani, S. Pol, and P. Cacoub Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 45 2007 123 125 (Pubitemid 46684453)
84. E. Vispo, P. Barreiro, J.A. Pineda, J.A. Mira, I. Maida, and L. Martín-Carbonero Low response to pegylated interferon plus ribavirin in HIv-infected patients with chronic hepatitis C treated with abacavir Antivir Ther 13 2008 429 437 (Pubitemid 352016736)
85. J.A. Mira, L. Lopez-Cortes, P. Barreiro, C. Tural, M. Torres-Tortosa, and I. De Los Santos Gil Efficacy of pegylated interferon plsu ribavirin treatment in HIV/HCV coinfected patients receiving abacavir plus lamivudine or tenofovir plsu either lamivudine or emtricitabine as nucleoaide analogue backbone J Antimicrob Chemother 62 2008 1365 1373
86. P. Labarga, E. Vispo, P. Barreiro, S. Rodríguez-Novoa, J. Pinilla, and J. Morello Rate and predictors of success in the re-treatment of chronic hepatitis C in HIV/HCV coinfected patients with prior non-response or relapse J Acquir Immune Defic Syndr 53 2010 364 368
87. V. Soriano, M. Peters, and S. Zeuzem New therapies for HCV infection Clin Infect Dis 48 2009 313 320
88. K. Seden, D. Back, and S. Khoo New directly acting antivirals for hepatitis C: potential for interactions with antiretrovirals J Antimicrob Chemother 65 2010 1079 1085
89. V. Soriano, A. Perelson, and F. Zoulim Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 62 2008 1 4 (Pubitemid 351865869)
90. Sulkowski M, Dieterich D, Sherman K, Rockstroh J, Adda N, Manke N, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN and RBV in HIV/HCV-coinfected patients. CROI 2011, Boston, MA [abstract 146LB].
91. M. Rizzetto HDV: thirty years later Dig Liver Dis 43 Suppl 2011 15 18
92. Soriano V, Grint D, d'Arminio-Monforte A, Horban A, Leen C, Poveda E, et al. Delta hepatitis in HIV-infected individuals in Europe. AIDS. En prensa.
93. H. Wedemeyer, C. Yurdaydin, G. Dalekos, A. Erhardt, Y. akaloglu, and H. Degertedin Peginterferon plus adefovir versus either drug alone for hepatitis delta N Engl J Med 364 2011 322 331
94. J. Sheldon, B. Ramos, C. Toro, P. Ríos, J. Martínez- Alarcón, and M. Bottecchia Does treatment of hepatitis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDV coinfected patients? Antivir Ther 13 2008 97 102 (Pubitemid 351541678)
95. L. Martin-Carbonero, T. Teixeira, E. Poveda, Z. Plaza, E. Vispo, and J. González-Lahoz Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues AIDS 25 2011 73 79